ZDHHC9 promotes colon tumor growth by inhibiting effector T cells

Chong,Xiaodan; Zhu,Lingxi; Yu,Dong; Chen,Shasha; Wang,Guang; Yu,Qingzhuo; Ma,Xianwei; Xu,Jing; Chen,Haitao; An,Huazhang

doi:10.3892/ol.2022.13591

ZDHHC9 promotes colon tumor growth by inhibiting effector T cells

Authors:
- Xiaodan Chong
- Lingxi Zhu
- Dong Yu
- Shasha Chen
- Guang Wang
- Qingzhuo Yu
- Xianwei Ma
- Jing Xu
- Haitao Chen
- Huazhang An
View Affiliations

Affiliations: Clinical Cancer Institute, Translational Medicine Center, Naval Medical University, Shanghai 200433, P.R. China, Center of Translational Medicine, Naval Medical University, Shanghai 200433, P.R. China, Department of Geriatrics, Changhai Hospital, Naval Medical University, Shanghai 200433, P.R. China
Published online on: November 10, 2022 https://doi.org/10.3892/ol.2022.13591
Article Number: 5
Copyright: © Chong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zinc finger DHHC‑type palmitoyltransferase 9 (ZDHHC9) has been reported to play an important role in the occurrence and development of several types of cancer. However, its effects on colon cancer growth remain unclear. Using Gene Expression Profiling Interactive Analysis and Tumor Immune Estimation Resource, data obtained from The Cancer Genome Atlas were analyzed, and the results showed that ZDHHC9 was highly expressed in colon cancer and that patients with higher ZDHHC9 expression levels had a worse prognosis. Inhibition of ZDHHC9 expression promoted the proliferation of colon cancer cells in vitro but decreased their growth in vivo. Additionally, inhibition of ZDHHC9 expression in cancer cells enhanced CD8⁺ T cell‑mediated cytotoxicity in vitro and increased CD8^₊ T infiltration and activation in vivo. Furthermore, ZDHHC9 promoted IFN‑γ‑induced JAK/STAT1 activation and upregulated programmed death‑ligand 1 (PD‑L1) expression in colon cancer cells. In conclusion, the present findings showed that ZDHHC9 promoted colon cancer growth by upregulating the expression of PD‑L1 and inhibiting the function of CD8⁺ T cells.

View Figures

View References

1	Chen SJ, Wang SC and Chen YC: The immunotherapy for colorectal cancer, lung cancer and pancreatic cancer. Int J Mol Sci. 22:128362021. View Article : Google Scholar : PubMed/NCBI
2	Fiorica F, Belluomini L, Giuliani J, Urbini B, Milella M, Frassoldati A, Pilotto S and Giorgi C: Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: A case report. Immunotherapy. 13:971–976. 2021. View Article : Google Scholar : PubMed/NCBI
3	Morad G, Helmink BA, Sharma P and Wargo JA: Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 185:5762022. View Article : Google Scholar : PubMed/NCBI
4	Dersh D, Holly J and Yewdell JW: A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol. 21:116–128. 2021. View Article : Google Scholar : PubMed/NCBI
5	Watson RA, Tong O, Cooper R, Taylor CA, Sharma PK, de Los Aires AV, Mahé EA, Ruffieux H, Nassiri I, Middleton MR and Fairfax BP: Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8(+) T cell clone size and cytotoxicity. Sci Immunol. 6:eabj88252021. View Article : Google Scholar : PubMed/NCBI
6	Kouskou M, Thomson DM, Brett RR, Wheeler L, Tate RJ, Pratt JA and Chamberlain LH: Disruption of the Zdhhc9 intellectual disability gene leads to behavioural abnormalities in a mouse model. Exp Neurol. 308:35–46. 2018. View Article : Google Scholar : PubMed/NCBI
7	Masurel-Paulet A, KalscheuerV M, Lebrun N, Hu H, Levy F, Thauvin-Robinet C, Darmency-Stamboul V, El Chehadeh S, Thevenon J, Chancenotte S, et al: Expanding the clinical phenotype of patients with a ZDHHC9 mutation. Am J Med Genet A. 64:789–795. 2014. View Article : Google Scholar : PubMed/NCBI
8	Hawkins E, Akarca D, Zhang M, Brkić D, Woolrich M, Baker K and Astle D: Functional network dynamics in a neurodevelopmental disorder of known genetic origin. Hum Brain Mapp. 41:530–544. 2020. View Article : Google Scholar : PubMed/NCBI
9	Shimell JJ, Shah BS, Cain SM, Thouta S, Kuhlmann N, Tatarnikov I, Jovellar DB, Brigidi GS, Kass J, Milnerwood AJ, et al: The X-linked intellectual disability gene Zdhhc9 is essential for dendrite outgrowth and inhibitory synapse formation. Cell Rep. 29:2422–2437. 2019. View Article : Google Scholar : PubMed/NCBI
10	Schirwani S, Wakeling E, Smith K, Study DDD and Balasubramanian M: Expanding the molecular basis and phenotypic spectrum of ZDHHC9-associated X-linked intellectual disability. Am J Med Genet A. 176:1238–1244. 2018. View Article : Google Scholar : PubMed/NCBI
11	Liu P, Jiao B, Zhang R, Zhao H, Zhang C, Wu M, Li D, Zhao X, Qiu Q, Li J and Ren R: Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic Nras. Leukemia. 30:1225–1228. 2016. View Article : Google Scholar : PubMed/NCBI
12	Chen X, Ma H, Wang Z, Zhang S, Yang H and Fang Z: EZH2 palmitoylation mediated by ZDHHC5 in p53-mutant glioma drives malignant development and progression. Cancer Res. 77:4998–5010. 2017. View Article : Google Scholar : PubMed/NCBI
13	Noland CL, Gierke S, Schnier PD, Murray J, Sandoval WN, Sagolla M, Dey A, Hannoush RN, Fairbrother WJ and Cunningham CN: Palmitoylation of TEAD transcription factors is required for their stability and function in hippo pathway signaling. Structure. 24:179–186. 2016. View Article : Google Scholar : PubMed/NCBI
14	Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, Wei Y, Xia W, Hou J, Qiu Y and Hung MC: Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 29:83–86. 2019. View Article : Google Scholar : PubMed/NCBI
15	Mansilla F, Birkenkamp-Demtroder K, Kruhøffer M, Sørensen FB, Andersen CL, Laiho P, Aaltonen LA, Verspaget HW and Orntoft TF: Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups. Br J Cancer. 96:1896–1903. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sharma P and Allison JP: Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20:75–76. 2020. View Article : Google Scholar : PubMed/NCBI
17	Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C, Agoussi S, et al: Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 24:1877–1886. 2018. View Article : Google Scholar : PubMed/NCBI
18	Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H and Wang C: Immunotherapy: Reshape the tumor immune microenvironment. Front Immunol. 13:8441422022. View Article : Google Scholar : PubMed/NCBI
19	Yenyuwadee S, Aliazis K, Wang Q, Christofides A, Shah R, Patsoukis N and Boussiotis VA: Immune cellular components and signaling pathways in the tumor microenvironment. Semin Cancer Biol. 86:187–201. 2022. View Article : Google Scholar : PubMed/NCBI